“After the human genome was sequenced, Personalized Medicine became an end goal, driving both academia and the pharma/biotech industry to find and target cellular pathways and drug therapies that are unique to an individual patient. The final webinar in the series will help us better understand The Impact of Personalized Medicine, what we can expect to gain and where we stand to lose.”
Dr. Tenenbaum will be joined by Amy P. Abernethy, M.D., Associate Professor of Medicine, Duke University School of Medicine and Director of the Duke Cancer Care Research Program; and Abhijit “Ron” Mazumder, Ph.D., Global Head, Research & Product Development, Janssen Diagnostics, Janssen Pharmaceutical companies of Johnson and Johnson.
When: Tuesday, May 7, 2013, 2:30–4:00 pm ET. Register here.
Cancer Commons’ partner Smart Patients launched publicly today after a presentation at the TEDMED conference in Washington, DC. Smart Patients is an online discussion platform for cancer patients and their caregivers that will enable them to learn from each other and improve their care. The free website lets users share insights about personal treatment experiences, discuss breaking science, and search for clinical trials, as shown in this demo video:
Cancer Commons will be partnering with Smart Patients to bring patients’ insights to our Rapid Learning Communities. Cancer Commons’ research collaborators will be able to access anonymous insights from Smart Patients discussions. These insights will help Cancer Commons in its mission to make sure every cancer patient is treated according to what’s working best for similar patients.
A multicenter “dream team” of scientists, led by the University of California, San Francisco (UCSF), has embarked on a groundbreaking $10M initiative in personalized medicine, to overcome therapeutic resistance in patients with advanced prostate cancer. The grant is provided by Stand Up To Cancer and the Prostate Cancer Foundation.
“Do-It-Yourself-Medicine: Patients are sidestepping clinical research and using themselves as guinea pigs to test new treatments for fatal diseases. Will they hurt themselves, or science?”
From the article by Jeff Akst:
“When you have gigabytes of data, perhaps hundreds of gigabytes, for each patient, that’s more data than has existed in all clinical trials combined up until a couple of years ago,” says Marty Tenenbaum, who in 2010 founded Cancer Commons, a database that collates real-time patient data and up-to-the-moment basic medical research to inform cancer treatment.
Personalized Oncology – Fulfilling the Promise for Today’s Patients
In honor of the 20th anniversary of the Molecular Medicine Tri-Conference, CHI and Cancer Commons will present a plenary panel on Personalized Oncology. Innovations such as NGS and The Cancer Genome Atlas have revealed that cancer comprises hundreds of distinct molecular diseases. Early clinical successes with targeted therapies suggest that cancer might one day be managed as a chronic disease using an evolving cocktail of drugs.Representing all five conference channels, Diagnostics, Therapeutics, Clinical, Informatics, and Cancer, a panel of experts will lead a highly interactive exploration of what it will take to realize this vision in the near future. Continue reading…
“Patients Take the Lead in Clinical Whole Genome Sequencing”
From the article by Catherine Shaffer:
“Elizabeth Iorns, a representative of Science Exchange, said many of its providers are CLIA certified, and that the group is planning to expand into clinical services in partnership with Cancer Commons, a nonprofit open science initiative working toward bringing next-generation genomics technologies to patients.”
“Trial and error: Biotechs, patients, FDA search for faster, cheaper ways to develop drugs.”
From the article by Ron Leuty:
“Take Marty Tenenbaum, a metastatic melanoma survivor who has led efforts to link patients, researchers and companies in an open-science initiative, called Cancer Commons. His thinking is the more that patients know clinical trial results — and, importantly, report their own — the faster patients will populate the right clinical trials that are right for them.”
Dr. Tenenbaum to speak at the Personalized Medicine World Conference on January 28, 2013.
The 5th Annual Personalized Medicine World Conference on January 28-29 in Silicon Valley, provides an opportunity to learn from and engage in dialogue to further the field of personalized medicine. PMWC 2013 will bring together CEOs, entrepreneurs, researchers, clinicians, regulators and payers to present the latest progress and next challenges for the implementation of personalized medicine within a framework to address the coverage barriers. Featuring the premier leaders in the field, the Conference offers an opportunity to share best practices and build on lessons learned.
Cancer Commons congratulates our board member, Dr. Peter Yu, who has been elected ASCO’s President for the 2014-2015 term. Dr. Yu will take office as President-Elect during the ASCO Annual Meeting in Chicago in June 2013.
“I am both honored and privileged by the opportunity to lead ASCO,” said Dr. Yu. “I have been fortunate to serve the Society for many years in a volunteer capacity, and in doing so, have developed a depth and breadth of knowledge and experience on issues that are important for the advancement of cancer science and care. As President of the Society, I look forward to working collaboratively with the membership, staff and Board of Directors to further advance the ASCO mission and vision.”